Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$5.04 - $9.95 $46,428 - $91,659
-9,212 Reduced 13.37%
59,664 $555,000
Q3 2023

Nov 14, 2023

SELL
$6.55 - $9.37 $96,953 - $138,694
-14,802 Reduced 17.69%
68,876 $451,000
Q2 2023

Aug 09, 2023

BUY
$7.66 - $9.5 $37,020 - $45,913
4,833 Added 6.13%
83,678 $680,000
Q1 2023

May 15, 2023

BUY
$8.32 - $11.75 $77,267 - $109,122
9,287 Added 13.35%
78,845 $675,000
Q4 2022

Feb 14, 2023

BUY
$7.65 - $14.43 $50,658 - $95,555
6,622 Added 10.52%
69,558 $644,000
Q3 2022

Nov 10, 2022

BUY
$8.9 - $12.86 $41,429 - $59,863
4,655 Added 7.99%
62,936 $649,000
Q2 2022

Aug 11, 2022

BUY
$7.31 - $12.84 $33,830 - $59,423
4,628 Added 8.63%
58,281 $583,000
Q1 2022

May 12, 2022

BUY
$9.74 - $17.69 $212,185 - $385,376
21,785 Added 68.36%
53,653 $660,000
Q4 2021

Feb 14, 2022

BUY
$16.88 - $23.31 $13,402 - $18,508
794 Added 2.56%
31,868 $553,000
Q3 2021

Nov 16, 2021

BUY
$16.82 - $25.75 $522,664 - $800,155
31,074 New
31,074 $558,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $581M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Cetera Advisor Networks LLC Portfolio

Follow Cetera Advisor Networks LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Advisor Networks LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Advisor Networks LLC with notifications on news.